EyePoint (EYPT) Share-based Compensation (2010 - 2026)
EyePoint (EYPT) posted Share-based Compensation of $58.3 million for Q1 2026, up 2464.89% sequentially from $2.3 million in Q4 2025, and up 6356.26% YoY from $903000.0 in Q1 2025.
Analysis
EyePoint (EYPT) Share-based Compensation (2010 - 2026) Analysis & Trends
EyePoint has reported Share-based Compensation for 17 years, with the latest figure at $58.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 6356.26% year-over-year to $58.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.3 million (up 260.52% YoY) and the FY2025 annual result came in at $21.3 million, down 42.03% from the prior year.
- Share-based Compensation grew to $58.3 million in Q1 2026 per EYPT's latest filing, from $2.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $58.3 million in Q1 2026 and troughed at -$8.5 million in Q4 2023.
- A 5-year average of $6.2 million and a median of $3.2 million in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation jumped 67120.0% in 2022, then slumped 351.92% in 2023.
- Over 5 years, Share-based Compensation stood at $3.4 million in 2022, then plunged by 351.92% to -$8.5 million in 2023, then soared by 193.3% to $7.9 million in 2024, then sank by 71.23% to $2.3 million in 2025, then soared by 2464.89% to $58.3 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $58.3 million, $2.3 million, and -$132000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 50.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 50.40 Mn |
| Mar 31, 2026 | 58.30 Mn |
| Dec 31, 2025 | 6.75 Mn |
| Sep 30, 2025 | 9.44 Mn |
| Jun 30, 2025 | 9.48 Mn |
| Mar 31, 2025 | 9.39 Mn |
| Dec 31, 2024 | 7.90 Mn |
| Sep 30, 2024 | 7.70 Mn |
| Jun 30, 2024 | 8.70 Mn |
| Mar 31, 2024 | 12.70 Mn |
| Dec 31, 2023 | 3.59 Mn |
| Sep 30, 2023 | 6.34 Mn |
| Jun 30, 2023 | 6.17 Mn |
| Mar 31, 2023 | 6.07 Mn |
| Dec 31, 2022 | 3.36 Mn |
| Sep 30, 2022 | 4.03 Mn |
| Jun 30, 2022 | 4.14 Mn |
| Mar 31, 2022 | 3.97 Mn |
| Dec 31, 2021 | 2.81 Mn |
| Sep 30, 2021 | 2.47 Mn |